This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
by Zacks Equity Research
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Reasons to Retain IART Stock in Your Portfolio for Now
by Zacks Equity Research
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2
by Zacks Equity Research
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
CAH Stock Gains on the Launch of Kendall SmartFlow Compression System
by Zacks Equity Research
Cardinal Health launches the next generation of the Kendall Compression Series, Kendall SCD SmartFlow Compression System, to aid pain relating to venous stasis.
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
by Zacks Equity Research
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Chemed Stock Hurt by Roto-Rooter Softness, Macro Issues Dent Growth
by Zacks Equity Research
The ongoing global economic conditions, such as general labor, supply chain and inflationary pressure, along with political and regulatory developments, are escalating expenses for CHE.
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
by Zacks Equity Research
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom and OURA Ink Partnership for Metabolic Health Innovation
by Zacks Equity Research
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being.
MDT Stock Gains From FDA Approval for Its InPen App
by Zacks Equity Research
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
Cencora Rallies 19.7% Year to Date: What's Driving the Stock?
by Zacks Equity Research
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
by Zacks Equity Research
MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.
Veeva Stock May Gain on the Launch of GenAI Features in Vault CRM
by Zacks Equity Research
VEEV announces GenAI capabilities, CRM Bot and Voice Control, for its Vault CRM.
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?
by Zacks Equity Research
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
by Zacks Equity Research
Henry Schein inked a new agreement to acquire Acentus to enhance its ability to deliver CGM products directly to patients' homes.
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
by Zacks Equity Research
Align Technology achieves a CE mark for the Invisalign Palatal Expander System.
GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects
by Zacks Equity Research
GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.
HealthEquity Gains 54.6% YTD: What's Driving the Stock?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
End Market Growth, New Acquisitions Drive Thermo Fisher's Shares
by Zacks Equity Research
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
Stryker Stock May Gain From Oculan Lighting Platform's Launch
by Zacks Equity Research
SYK launches the Oculan Lighting Platform to improve lighting conditions in the operating rooms and allow surgeons to perform with more accuracy.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
by Zacks Equity Research
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
by Zacks Equity Research
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Patterson Companies Stock Up Following Latest Partnership Extension
by Zacks Equity Research
PDCO's latest agreement with PDS Health to extend their deal is likely to streamline operations, optimize efficiency and maximize profitability.
Medtronic Q2 Earnings and Revenues Top, Stock Down on Trimmed '25 View
by Zacks Equity Research
MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.